Core Viewpoint - The stock of Qiming Medical-B (02500) rose over 10% in late trading, currently up 9.8% at HKD 3.36, with a trading volume of HKD 13.76 million [1] Group 1: Investment Activity - Kunbo Medical plans to acquire a 1.05% stake in Qiming Medical for a total consideration of USD 15 million [1] - Qiming Medical stated that the sale represents an appropriate opportunity to monetize its investment as a minority financial investor [1] Group 2: Financial Strategy - By divesting non-core business investments, Qiming Medical aims to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Product Development - Qiming Medical has submitted all application materials for CE MDR certification of the Cardiovalve transcatheter tricuspid valve replacement system to the European notification agency, marking a significant step in the product's market entry process in Europe [1] - This development further enhances Qiming Medical's treatment matrix for tricuspid valves, building on its established mitral and pulmonary valve product lines [1]
启明医疗-B尾盘涨超10% 公司近期出售德晋医疗1.05%股权 有助于聚焦核心业务